Phase I Clinical Trial of Adoptive Transfer of Autologous Folate Receptor alpha Redirected T Cells for Recurrent High Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer
Brief description of study
This is a Phase I study evaluating the safety and feasibility of intraperitoneal administered lentiviral transduced MOv19-BBz CAR-T cells in 4 cohorts with or without cyclophosphamide + fludarabine in a 3+3 dose escalation design. Up to 18 evaluable subjects will be treated.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
-
Conditions:
TBD
-
Age: - 99 Years
-
Gender: All
Updated on
09 Mar 2024.
Study ID: 830111
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For cancer trials contact EmergingMed: 1-855-216-0098 or PennCancerTrials@emergingmend.com